Go to the list of all blogs
M. Benett's Avatar
published in Blogs
May 21, 2026
Ichor Holdings (ICHR) Maintains Momentum with +2% Monthly and +31% Quarterly Gains

Ichor Holdings (ICHR) Maintains Momentum with +2% Monthly and +31% Quarterly Gains

Key Takeaways

  • Ichor Holdings, Ltd. (ICHR) stock rose approximately 2% over the past 30 days, supported by positive analyst sentiment and sector momentum.
  • Over the last quarter, the stock advanced roughly 31%, driven by improving semiconductor demand and operational recovery.
  • Q1 2026 earnings beat expectations on both revenue and non-GAAP earnings, signaling margin expansion.
  • Multiple analyst price target increases and a shareholder-approved annual meeting contributed to investor confidence.
  • Macro factors including semiconductor capital equipment spending trends provided additional tailwinds.

A Closer Look at Ichor Holdings’ Business and Market Role

Ichor Holdings, Ltd. designs, engineers, and manufactures critical fluid delivery subsystems and components primarily for semiconductor capital equipment. The company focuses on high-precision manufacturing for original equipment manufacturers in the semiconductor industry, while also maintaining exposure to defense, aerospace, and medical sectors. As a key supplier in the semiconductor supply chain, Ichor Holdings, Ltd. tends to benefit from cyclical upswings in capital equipment spending, which can directly influence its revenue and stock price during periods of industry recovery.

Recent Stock Performance: 30 Days and the Quarter

Over the last 30 days, Ichor Holdings, Ltd. (ICHR) stock rose approximately 2%, moving from around 64.52 to 65.76. The movement appeared relatively steady with moderate volatility tied to earnings reactions and analyst updates. Over the past quarter, the stock climbed roughly 31%, advancing from approximately 50.35 to 65.76. This quarterly performance reflected a sustained upward trend supported by improving fundamentals and broader market sentiment toward semiconductor suppliers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Key Drivers Behind the Recent 30-Day Move

Positive analyst actions formed a primary catalyst, with several firms raising price targets following the May earnings release. Ichor Holdings, Ltd. reported first-quarter 2026 revenue of 256.1 million and non-GAAP earnings per share of 0.15, both ahead of consensus estimates. Although the initial reaction included some volatility, subsequent upgrades and reaffirmed buy ratings helped stabilize and lift the share price. Additional factors included shareholder approval of 2026 annual meeting proposals and the launch of a 200 million at-the-market equity program, which provided financial flexibility without immediate negative sentiment. Sector-wide momentum in semiconductor materials further supported the modest gains.

Factors Fueling the Strong Quarterly Performance

The broader quarterly advance stemmed from sustained semiconductor industry recovery and improving operational metrics at Ichor Holdings, Ltd. Revenue growth and gross margin expansion signaled renewed demand for fluid delivery systems amid rising capital equipment orders. Macroeconomic conditions, including stable interest rate expectations and resilient technology spending, created a favorable backdrop. Institutional investor interest increased as the company demonstrated margin recovery and guidance for profitability in subsequent quarters. Competitive positioning within the semiconductor supply chain amplified these gains, as investors rotated into suppliers with clear visibility into upcoming orders.

What to Watch for ICHR Going Forward

Investors should monitor upcoming quarterly results for continued revenue growth and margin trends. Industry developments in semiconductor capital equipment spending will remain key, alongside any updates on customer order backlogs. Macroeconomic factors such as interest rate policy and overall technology demand could influence sentiment. Strategic moves including potential partnerships or capacity expansions may also affect investor outlook. Risks to watch include supply chain disruptions and changes in customer capital expenditure plans. From what I see, keeping an eye on these areas will be important for assessing the next phase of the stock’s movement.

Exploring Tickeron’s Trending AI Robots for Trading Insights

In my analysis process, I sometimes review automated strategies to see how they align with broader market trends. Tickeron’s Trending AI Robots page showcases a curated selection of top-performing artificial intelligence trading bots. Tickeron offers hundreds of AI trading bots trading thousands of tickers, but only the highest-performing and most relevant bots appear in this section. Bots vary in strategy, timeframe, and performance metrics, allowing users to explore automated approaches suited to different market conditions. Investors seeking data-driven trading insights can review the latest performance details on the Trending AI Robots page.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: ICHR

ICHR's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ICHR turned positive on September 04, 2026. Looking at past instances where ICHR's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ICHR's RSI Indicator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Momentum Indicator moved above the 0 level on September 23, 2026. You may want to consider a long position or call options on ICHR as a result. In 66 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

ICHR moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICHR advanced for three days, in 246 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 167 of 209 cases where ICHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ICHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.571) is normal, around the industry mean (8.078). P/E Ratio (33.557) is within average values for comparable stocks, (161.623). Projected Growth (PEG Ratio) (0.251) is also within normal values, averaging (0.801). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.761) is also within normal values, averaging (27.897).

The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Lam Research Corp (NASDAQ:LRCX), Applied Materials (NASDAQ:AMAT), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 63.66B. The market cap for tickers in the group ranges from 326.86K to 671.68B. ASML holds the highest valuation in this group at 671.68B. The lowest valued company is AVSR at 326.86K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 2%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was 11%. INTT experienced the highest price growth at 28%, while SMTK experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was 15%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 34
Price Growth Rating: 42
SMR Rating: 71
Profit Risk Rating: 59
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
ICHR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company whose subsidiary manufactures gas and chemical delivery systems for semiconductor process equipment

Industry ElectronicProductionEquipment

Industry
Semiconductors
Address
3185 Laurelview Court
Phone
+1 510 897-5200
Employees
2448
Web
https://www.ichorsystems.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.